Adial Pharmaceuticals, Inc. (ADIL)
Chart Events
Performance Outlook
| Previous Close | 1.4200 |
| Open | 1.5200 |
| Bid | 1.4400 x 1400 |
| Ask | 1.4600 x 1200 |
| Day's Range | 1.3900 - 1.5400 |
| 52 Week Range | 1.1400 - 5.0800 |
| Volume | |
| Avg. Volume | 114,765 |
| Market Cap | 30.477M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0040 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter Ended first quarter with cash and cash equivalents of $12.7 million CHARLOTTESVILLE, Va., May 16, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”) a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorder
- GlobeNewswire
Maravai LifeSciences Reports First Quarter 2022 Financial Results
Affirms Revenue Guidance and Raises Adjusted EBITDA and Adjusted EPS GuidanceSAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2022, together with other business updates. Highlights include: Record quarterly revenue of $244.3 million, an increase of 65% over the prior year;Nucl
- GlobeNewswire
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major unmet medical needs, has entered into a research collaboration agreement with the University of California San Diego (UC San Diego), a leading education and research university, and Dr. Peter Ernst, DVM, PhD, Professor of Pathology and an expert
